FDA reaffirms its faith in Xarelto

Rivaroxaban (Xarelto), the anticoagulant at the centre of a large controversial trial, has been given the all clear by the US Food and Drug Administration.

The FDA analysis has found that a faulty, point-of-care device used for measuring INR in the warfarin arm did not substantially alter the results of the ROCKET Atrial Fibrillation trial, which led to the drug’s approval.

The device was recalled for giving falsely low readings during the trial, resulting a question mark over rivaroxaban’s safety and efficacy and